<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611024</url>
  </required_header>
  <id_info>
    <org_study_id>PM1183-A-014-15</org_study_id>
    <nct_id>NCT02611024</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors</brief_title>
  <official_title>Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination
      with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD)
      of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with selected advanced solid tumors will be divided into two groups: the PM01183 Escalation Group and the Irinotecan Escalation Group. Each group will have a different dose escalation scheme.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>48 months</time_frame>
    <description>The MTD for each group will be the lowest dose level explored during dose escalation which one third or more of evaluable patients develops DLT in Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Dose (RD)</measure>
    <time_frame>48 months</time_frame>
    <description>The RD for each groupwill be the highest dose level explored during dose escalation in which fewer than one third of evaluable patients develop DLT during Cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Since start of the treatment until 30 days after the last administration of study treatment; or until start of a new antitumor therapy or death</time_frame>
    <description>AEs will be graded according to the NCI-CTCAE v.4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>48 months</time_frame>
    <description>Pharmacokinetic Outcome Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>48 months</time_frame>
    <description>Pharmacokinetic Outcome Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution based on the terminal half-life (Vz)</measure>
    <time_frame>48 months</time_frame>
    <description>Pharmacokinetic Outcome Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>48 months</time_frame>
    <description>Pharmacokinetic Outcome Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>48 months</time_frame>
    <description>Pharmacokinetic Outcome Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>48 months</time_frame>
    <description>Pharmacokinetic Outcome Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antitumor response</measure>
    <time_frame>Start treatment until PD, other antitumor therapy, death or until 12 months after the inclusion of the last evaluable patient in the study (end of study), whichever occurs first.</time_frame>
    <description>Evaluable and measurable as per RECIST v.1.1 or RANO for Gliobastoma patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From the date of first infusion of study treatment to the date of progression or death or until 12 months after the inclusion of the last evaluable patient in the study (end of study), whichever occurs first.</time_frame>
    <description>Time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the PFS will be censored on the date of last tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of first infusion of study treatment to the date or death or until 12 months after the inclusion of the last evaluable patient in the study (end of study), whichever occurs first.</time_frame>
    <description>Time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death will be censored at the last date they are known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Glioblastoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Mesothelioma</condition>
  <condition>Gastroenteropancreatic Neuroendocrine Tumor</condition>
  <condition>SCLC</condition>
  <condition>Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>PM01183 Escalation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PM01183 1.0 mg/m^2 D1 60 min (-5/+20 min) i.v. infusion q3wk
Irinotecan 75 mg/m^2 D1-8 90 min (-5/+30 min) i.v. infusion q3wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan Escalation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PM01183 3.0 mg/m^2 D1 60 min (-5/+20 min) i.v. infusion q3wk
Irinotecan 15 mg/m^2 D1-8 90 min (-5/+30 min) i.v. infusion q3wk</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lurbinectedin (PM01183)</intervention_name>
    <description>lurbinectedin (PM01183) 4 mg vials</description>
    <arm_group_label>Irinotecan Escalation Group</arm_group_label>
    <arm_group_label>PM01183 Escalation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>irinotecan 40 mg, 100 mg or 300 mg vials</description>
    <arm_group_label>Irinotecan Escalation Group</arm_group_label>
    <arm_group_label>PM01183 Escalation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily signed and dated written informed consent prior to any specific-study
             procedure.

          2. Age ≥ 18 years.

          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1.

          4. Life expectancy ≥ 3 months.

          5. No more than two prior lines of cytotoxic-containing chemotherapy regimens for
             advanced disease. There is no limit for prior targeted therapy, hormonal therapy and
             immunotherapy (such as nivolumab).

          6. Histologically or cytologically confirmed diagnosis of advanced disease of any of the
             following tumor types:

               1. Glioblastoma.

               2. Soft-tissue sarcoma [excluding gastrointestinal stromal tumors (GIST)].

               3. Endometrial carcinoma.

               4. Epithelial ovarian carcinoma (including primary peritoneal disease and/or
                  fallopian tube carcinomas and/or endometrial adenocarcinomas) regardless of
                  platinum sensitivity.

               5. Mesothelioma.

               6. Gastroenteropancreatic neuroendocrine tumors (GEP-NET).

               7. Small cell lung cancer (SCLC).

               8. Pancreatic adenocarcinoma.

               9. Gastric carcinoma.

              10. Colorectal carcinoma (CRC).

          7. Expansion phase: Tumor-specific cohort(s) at the RD:

               1. Measurable disease according to Response Evaluation Criteria in Solid Tumors
                  (RECIST) v.1.1.

                  For patients with glioblastoma: Measurable disease according to RECIST v.1.1 and
                  RANO criteria.

               2. Documented disease progression per RECIST v.1.1 during or immediately after last
                  therapy according to any of the aforementioned criteria.

             For patients with glioblastoma: Documented disease progression per RECIST v.1.1 and
             RANO criteria.

          8. At least three weeks since the last anticancer therapy (excluding immunotherapy that
             must be at least two weeks, provided that is not combined with chemotherapy),
             including investigational drugs and radiotherapy, and at least six weeks since
             nitrosoureas and mitomycin C (systemic).

             For patients with glioblastoma: at least 12 weeks since the end of radiotherapy,
             except if:

               1. The patient has a new lesion outside of the radiotherapy field, or

               2. The patient has undergone brain surgery to remove the tumor before study entry,
                  and progressive disease has been confirmed histologically.

          9. Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before
             inclusion in the study):

               1. Platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 9.0 g/dL and absolute neutrophil
                  count (ANC) ≥ 2.0 × 10^9/L.

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × the
                  upper limit of normal (ULN), even in the presence of liver metastases.

               3. Alkaline phosphatase (ALP) ≤ 2.5 × ULN (≤ 5 × ULN if disease-related/in the case
                  of liver metastases).

               4. Total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN.

               5. International Normalized Ratio (INR) &lt; 1.5 (except if patient is on oral
                  anticoagulation therapy).

               6. Calculated creatinine clearance (CrCL) ≥ 30 mL/minute (using Cockcroft-Gault
                  formula).

               7. Creatine phosphokinase (CPK) ≤ 2.5 × ULN.

               8. Albumin ≥ 3.0 g/dL(*).

         10. Recovery to grade ≤ 1 or to baseline from any adverse event (AE) derived from previous
             treatment (excluding alopecia and/or cutaneous toxicity and/or peripheral neuropathy
             and/or fatigue grade ≤ 2).

        (*)Albumin transfusion to increase the blood level in order to fulfill the inclusion
        criterion is strictly forbidden.

        Exclusion Criteria:

          1. Concomitant diseases/conditions:

               1. History or presence of unstable angina, myocardial infarction, congestive heart
                  failure, or clinically significant valvular heart disease within the previous
                  year.

               2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing
                  treatment.

               3. Myopathy or any clinical situation that causes significant and persistent
                  elevation of CPK (&gt; 2.5 × ULN in two different determinations performed one week
                  apart).

               4. Ongoing chronic alcohol consumption or cirrhosis with Child-Pugh score B or C.
                  Known Gilbert disease.

               5. Active uncontrolled infection.

               6. Known human immunodeficiency virus (HIV) infection. Known human immunodeficiency
                  virus (HIV) or known hepatitis C virus (HCV) infection or active hepatitis B.

               7. Any past or present chronic inflammatory colon and/or liver disease, past
                  intestinal obstruction, pseudo or sub-occlusion or paralysis.

               8. Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or
                  cardiac effusion rapidly increasing and/or necessitating prompt local treatment
                  within seven days.

               9. Any other major illness that, in the Investigator's judgment, will substantially
                  increase the risk associated with the patient's participation in this study.

          2. Prior treatment with PM01183, trabectedin (Yondelis®) or topoisomerase I inhibitors
             (irinotecan, topotecan, etc.). Prior topoisomerase inhibitors (e.g., irinotecan) are
             only allowed in patients with colorectal carcinoma.

          3. Prior bone marrow or stem cell transplantation, or radiation therapy in more than 35%
             of bone marrow.

          4. Known brain metastases or leptomeningeal disease involvement. Glioblastoma lesions
             (primary or locally advanced) are eligible. In SCLC, patients with brain metastases or
             leptomeningeal disease involvement are eligible provided they are radiologically
             stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging
             (note that the repeat imaging should be performed during study screening), clinically
             stable and without requirement of steroid treatment (patients taking steroids in the
             process of already being tapered within two weeks prior to screening are allowed).
             Brain CT-scan or MRI results must be provided at baseline.

          5. Women who are pregnant or breast feeding and fertile patients (men and women) who are
             not using an effective method of contraception.(*)

          6. Limitation of the patient's ability to comply with the treatment or follow-up
             protocol.

        (*)Women of childbearing potential (WOCBP) must agree to use an effective contraception
        method to avoid pregnancy during the course of the trial (and for at least three months
        after the last infusion). Fertile male patients must agree to refrain from fathering a
        child or donating sperm during the trial and for four months after the last infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pharma Mar Clinical Oncology</last_name>
    <email>clinicaltrials@pharmamar.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital -</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Cote, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Paz-Ares, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>María José Flor Oncala, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lurbinectedin</keyword>
  <keyword>PM01183</keyword>
  <keyword>Tumors</keyword>
  <keyword>Cancer</keyword>
  <keyword>Pharma Mar</keyword>
  <keyword>Edwing Sarcoma</keyword>
  <keyword>Synovial Sarcoma</keyword>
  <keyword>Sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

